Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Evans

Showing results (41-50 of 154) with videos related to

Pageof 16
Sort By:
Drug Design, Development and Therapy|December 24, 2013
Lixisenatide as add-on therapy to basal insulinDominique Xavier Brown, Emma Louise Butler, Marc Evans
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|December 11, 2012
A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practiceMarc Evans, Phil McEwan, Richard O'Shea, et al.
Drugs|May 27, 2004
Medical lipid-regulating therapy: current evidence, ongoing trials and future developmentsMarc Evans, Aled Roberts, Steve Davies, et al.
Diabetes, Obesity & Metabolism|September 18, 2020
A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer?Rebecca K Vincent, David M Williams, Marc Evans
Scientific Reports|February 23, 2019
Accelerating Neutron Tomography experiments through Artificial Neural Network based reconstructionDavide Micieli, Triestino Minniti, Llion Marc Evans, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 27, 2022
Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 InhibitorsRebecca Heath, Håkon Johnsen, W David Strain, et al.
Current Opinion in Lipidology|November 19, 2003
Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directionsAled W Roberts, Andrew Thomas, Alan Rees, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 19, 2015
Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?Marc Evans, Sylvie Dejager, Anja Schweizer, et al.
Diabetes, Obesity & Metabolism|June 3, 2004
Should we routinely measure a proxy for insulin resistance as well as improve our modelling techniques to better predict the likelihood of coronary heart disease in people with type 2 diabetes? For debateMarc Evans, Phil McEwan, John R Peters, et al.
Diabetes, Obesity & Metabolism|March 2, 2023
Estimating the value of sodium-glucose cotransporter-2 inhibitors within the context of contemporary guidelines and the totality of evidencePhil McEwan, Volker Foos, Becky Martin, et al.
Pageof 16

Showing results (41-50 of 154) with videos related to

Sort By:
Pageof 16
Drug Design, Development and Therapy|December 24, 2013
Lixisenatide as add-on therapy to basal insulinDominique Xavier Brown, Emma Louise Butler, Marc Evans
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|December 11, 2012
A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practiceMarc Evans, Phil McEwan, Richard O'Shea, et al.
Drugs|May 27, 2004
Medical lipid-regulating therapy: current evidence, ongoing trials and future developmentsMarc Evans, Aled Roberts, Steve Davies, et al.
Diabetes, Obesity & Metabolism|September 18, 2020
A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer?Rebecca K Vincent, David M Williams, Marc Evans
Scientific Reports|February 23, 2019
Accelerating Neutron Tomography experiments through Artificial Neural Network based reconstructionDavide Micieli, Triestino Minniti, Llion Marc Evans, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 27, 2022
Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 InhibitorsRebecca Heath, Håkon Johnsen, W David Strain, et al.
Current Opinion in Lipidology|November 19, 2003
Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directionsAled W Roberts, Andrew Thomas, Alan Rees, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 19, 2015
Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?Marc Evans, Sylvie Dejager, Anja Schweizer, et al.
Diabetes, Obesity & Metabolism|June 3, 2004
Should we routinely measure a proxy for insulin resistance as well as improve our modelling techniques to better predict the likelihood of coronary heart disease in people with type 2 diabetes? For debateMarc Evans, Phil McEwan, John R Peters, et al.
Diabetes, Obesity & Metabolism|March 2, 2023
Estimating the value of sodium-glucose cotransporter-2 inhibitors within the context of contemporary guidelines and the totality of evidencePhil McEwan, Volker Foos, Becky Martin, et al.
Pageof 16